Perrigo (NYSE: PRGO) is a publicly listed company headquartered in Dublin, Ireland that owns 3 consumer brands across 2 categories and makes and sells 1 consumer brand under licence without owning the name, and has 1 recorded transaction.[1][2]
Perrigo was founded in Michigan in 1887 and built its business on making store-brand versions of over-the-counter medicines, so its products are sold under supermarket and pharmacy labels rather than its own name. It has more recently bought consumer brands to sit alongside that business.
brands owned
2
categories
1
acquisitions recorded · 1 since 2015
0
divestitures recorded
Read from Perrigo's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan").
In the case of divestitures, including the disposition of the Rare Diseases Business and the separation of the Rx business, we may face difficulty in effectively transferring contracts, obligations, facilities, and personnel to the purchaser, while minimizing continued exposure to risks and liabilities of the divested business.
Headline figures from Perrigo's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $4.09bn to $4.25bn, an average of 0.8% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $4.25bn | $-1,122,200,000 | -26.4% | $-1,425,400,000 | $8.54bn | $3.6bn | 10-K | |
| $4.37bn | $112.9m | 2.6% | $-171,800,000 | $9.65bn | $3.58bn | 10-K | |
| $4.66bn | $151.9m | 3.3% | $-12,700,000 | $10.8bn | $3.63bn | 10-K | |
| $4.45bn | $78.9m | 1.8% | $-140,600,000 | $11bn | $4.07bn | 10-K | |
| $4.14bn | $410.4m | 9.9% | $-68,900,000 | $10.4bn | $2.92bn | 10-K | |
| $4.09bn | $265.2m | 6.5% | $-162,600,000 | $11.5bn | $3.53bn | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree →
Full portfolio, 3 brands, with sources → · Competitors by shared categories →
Perrigo bought the branded over-the-counter rights to Prevacid 24HR from GlaxoSmithKline for $61.5 million in cash, capitalising $61.7 million including closing costs as a brand intangible and amortising it over twenty years. What changed hands was the right to sell the brand over the counter rather than the underlying drug, which is how most of Perrigo's branded portfolio has been assembled.
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
| Filed | Form | What it declares |
|---|---|---|
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Departure or appointment of directors or officers | |
| 8-K | Departure or appointment of directors or officers; Regulation FD disclosure | |
| 8-K | Departure or appointment of directors or officers; Regulation FD disclosure | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Departure or appointment of directors or officers; Results of a shareholder vote | |
| 8-K | Completion of an acquisition or disposal of assets; Regulation FD disclosure | |
| 8-K | Results of operations and financial condition; Regulation FD disclosure | |
| 8-K | Entry into a material agreement; Creation of a direct financial obligation | |
| 8-K | Results of operations and financial condition | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition; Regulation FD disclosure |
Headlines link to the original publisher. Brandtree does not reproduce article text.
Perrigo owns 3 consumer brands tracked here, including Compeed, Prevacid 24HR and Steripod.
Yes. Perrigo is headquartered in Dublin, Ireland and was founded in 1887.
Perrigo is a publicly listed company owned by its shareholders; it trades as PRGO on the NYSE.
The most recent completed acquisition recorded here is Prevacid 24HR on 29 November 2019.
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.
Brandtree needs to remember this choice and does not set any other cookie unless you accept.
If you choose “Accept all”, we also use Google Analytics cookies to count visits and see which pages help, so we can improve the site.
If you choose “Accept required”, no analytics cookie is set. Google Analytics still receives a cookieless ping with the page address and your IP address. No advertising is used either way. Privacy policy